Cargando…

Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy: Validating the CAMD and AASL scores in China

BACKGROUND: We aimed to validate the predictive value of the cirrhosis, age, male sex, and diabetes (CAMD) score and age, albumin, sex, and liver cirrhosis (AASL) score for chronic hepatitis B (CHB) patients, treated with nucleos(t)ide analogues (NUCs) in Northeast China. METHODS: From January 2009...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shuai, Liu, Bingwei, Fan, Xuemei, Gao, Yang, Hong, Mingqi, Xu, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752533/ https://www.ncbi.nlm.nih.gov/pubmed/35170433 http://dx.doi.org/10.4103/sjg.sjg_527_21

Ejemplares similares

The GNU Control System at CAMD ; 2
por: Jines, P, et al.
Publicado: (1999)

High-throughput Toroidal Grating Beamline for Photoelectron Spectroscopy at CAMD
por: Kizilkaya, O, et al.
Publicado: (2014)

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
por: Sohn, Won, et al.
Publicado: (2017)

Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Antiviral therapy for chronic hepatitis B in China
por: Zheng, Xin, et al.
Publicado: (2014)

External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy
por: Gui, Honglian, et al.
Publicado: (2021)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
por: Tada, Toshifumi, et al.
Publicado: (2021)

Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy
por: Seo, Yeon Seok, et al.
Publicado: (2016)

Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
por: Chang, Jin Won, et al.
Publicado: (2021)

Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy: Erratum
Publicado: (2016)

Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients
por: Lee, Ji Hun, et al.
Publicado: (2022)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
por: Lee, Jaemin, et al.
Publicado: (2016)

Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment
por: Gokcen, Pinar, et al.
Publicado: (2022)

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
por: Varbobitis, Ioannis, et al.
Publicado: (2016)

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
por: Kamp, William M., et al.
Publicado: (2019)

Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization
por: Wang, Zhe-Xuan, et al.
Publicado: (2020)

Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents
por: Shin, Jung-ho, et al.
Publicado: (2016)

The Influence of Metabolic Factors in Patients with Chronic Viral Hepatitis C Who Received Oral Antiviral Treatment
por: Gavril, Oana Irina, et al.
Publicado: (2023)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
por: Chien, Rong-Nan, et al.
Publicado: (2022)

Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization
por: Lin, Po-Ting, et al.
Publicado: (2022)

Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
por: Kim, In Jung, et al.
Publicado: (2022)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral Treatment
por: Juday, Timothy, et al.
Publicado: (2010)

Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents
por: Chen, Yen-Chun, et al.
Publicado: (2020)

Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy
por: Lee, Hye Won, et al.
Publicado: (2019)

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
por: Kim, Sung Eun
Publicado: (2017)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis
por: Dultz, Georg, et al.
Publicado: (2013)

A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy
por: Saeki, Issei, et al.
Publicado: (2015)

Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
por: Thiele, Maja, et al.
Publicado: (2013)

Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
por: Shim, Jae-Jun, et al.
Publicado: (2016)

Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure
por: Lee, I-Cheng, et al.
Publicado: (2017)

Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib
por: Simão, Adélia
Publicado: (2016)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy
por: Alshuwaykh, Omar, et al.
Publicado: (2022)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
por: Chen, Yen-Chun, et al.
Publicado: (2022)

Antiviral Treatment among Pregnant Women with Chronic Hepatitis B
por: Fan, Lin, et al.
Publicado: (2014)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection
por: Huang, Sha, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_08l70v42e18qggkf6cgodpqloh